| 1.18 -0.02 (-1.67%) | 07-03 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.56 | 1-year : | 1.74 |
| Resists | First : | 1.33 | Second : | 1.49 |
| Pivot price | 1.23  |
|||
| Supports | First : | 1.09 | Second : | 0.9 |
| MAs | MA(5) : | 1.19 | MA(20) : | 1.26 |
| MA(100) : | 1.41 |
MA(250) : | 1.59  |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 30.7 |
D(3) : | 29 |
| RSI | RSI(14): 40.5 |
|||
| 52-week | High : | 3.06 | Low : | 0.92 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ OKYO ] has closed above bottom band by 27.4%. Bollinger Bands are 8.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.21 - 1.21 | 1.21 - 1.22 |
| Low: | 1.16 - 1.17 | 1.17 - 1.18 |
| Close: | 1.17 - 1.18 | 1.18 - 1.19 |
OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
Tue, 25 Jun 2024
OKYO Pharma (NASDAQ:OKYO) Shares Down 3.2% - Defense World
Mon, 24 Jun 2024
Promising Developments from OKYO Pharma on Dry Eye Disease and Neuropathic Pain Treatment - Proactive Investors USA
Wed, 08 May 2024
OKYO Pharma Announces Participation in May 2024 Investor Conferences - Yahoo Finance
Mon, 25 Mar 2024
OKYO Stock Quote Price and Forecast - CNN
Fri, 22 Mar 2024
OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of ... - Yahoo Finance
Mon, 12 Feb 2024
FDA grants IND clearance for OKYO Pharma's NCP treatment trial - Clinical Trials Arena
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 33 (M) |
| Held by Insiders | 1.364e+007 (%) |
| Held by Institutions | 25.7 (%) |
| Shares Short | 63 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.318e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -173.5 % |
| Return on Equity (ttm) | -2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.15 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.28 |
| Qtrly Earnings Growth | -0.7 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -8 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 48.08 |
| Dividend | 0 |
| Forward Dividend | 42520 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|